Identification of Parkinson's disease using MRI and genetic data from the PPMI cohort: an improved machine learning fusion approach.

Abstract

Objective: This study aim to leverage advanced machine learning techniques to develop and validate novel MRI imaging features and single nucleotide polymorphism (SNP) gene data fusion methodologies to enhance the early identification and diagnosis of Parkinson's disease (PD).

Methods: We leveraged a comprehensive dataset from the Parkinson's Progression Markers Initiative (PPMI), which includes high-resolution neuroimaging data, genetic single-nucleotide polymorphism (SNP) profiles, and detailed clinical information from individuals with early-stage PD and healthy controls. Two multi-modal fusion strategies were used: feature-level fusion, where we employed a hybrid feature selection algorithm combining Fisher discriminant analysis, an ensemble Lasso (EnLasso) method, and partial least squares (PLS) regression to identify and integrate the most informative features from neuroimaging and genetic data; and decision-level fusion, where we developed an adaptive ensemble stacking (AE_Stacking) model to synergistically integrate the predictions from multiple base classifiers trained on individual modalities.

Results: The AE_Stacking model achieving the highest average balanced accuracy of 95.36% and an area under the receiver operating characteristic curve (AUC) of 0.974, significantly outperforming feature-level fusion and single-modal models (p < 0.05). Furthermore, by analyzing the features selected across multiple iterations of our models, we identified stable brain region features [lh 6r (FD) and rh 46 (GI)] and key genetic markers (rs356181 and rs2736990 SNPs within the SNCA gene region; rs213202 SNP within the VPS52 gene region), highlighting their potential as reliable early diagnostic indicators for the disease.

Conclusion: The AE_Stacking model, trained on MRI and genetic data, demonstrates potential in distinguishing individuals with PD. Our findings enhance understanding of the disease and advance us toward the goal of precision medicine for neurodegenerative disorder.